Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 2Active not recruiting 2

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 7Thoracic 6Gastrointestinal 5Genitourinary 4Sarcoma 3Head & Neck 3Breast 3Gynecologic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Papillary renal cell carcinoma, sporadic 1Hereditary leiomyomatosis and renal cell cancer 1Fallopian Tube Mucinous Adenocarcinoma 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Contrast Media × Genitourinary × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04981509 2026-05-13

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT06330805 2026-03-09

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
70 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡